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A B S T R A C TObjectives: We assessed the performance of the UK Prospective Diabe-
tes Study (UKPDS) outcomes model in predicting the risk of myocardial
infarction (MI) and stroke in the Anglo-Danish-Dutch Study of Intensive
Treatment in People with Screen Detected Diabetes in Primary Care
(ADDITION-Europe) a trial cohort of patients with screen-detected type 2
diabetes from the United Kingdom, Denmark, and The Netherlands.
Methods: We estimated the 5-year accumulated risk of MI and stroke for
2899 screen-detected people with type 2 diabetes by using the UKPDS
outcomes model (version 1.3). We compared the predicted and actual
risks by country and by intervention group (routine care; intensive
multifactorial treatment). We assessed discrimination and goodness of
ﬁt by using area under receiver operating characteristic curves and the
Hosmer-Lemeshow chi-square test. Multiple imputations were used to
overcome missing data. Results: The UKPDS outcomes model overesti-
mated the risk of MI and stroke. Mean predicted/actual ratios of 5-year
accumulated risk were 2.31 for MI in the routine care group and 3.97 in
the intensive multifactorial treatment group and 1.59 and 1.48 for stroke,
respectively. The differences in absolute risk between the interventionsee front matter Copyright & 2013, International S
r Inc.
016/j.jval.2013.06.001
immons@mrc-epid.cam.ac.uk.
ondence to: Rebecca K. Simmons, MRC Epidemiolo
, Cambridge CB2 0QQ, UK.groups were underestimated for MI (observed vs. predicted: 0.0127 vs.
0.0009) and slightly overestimated for stroke (−0.0013 vs. −0.0004).
The area under the receiver operating characteristic curve was 0.72
(95% conﬁdence interval 0.66–0.79) for MI and 0.70 (95% conﬁdence
interval 0.64–0.77) for stroke. The Hosmer-Lemeshow test statistic
was nonsigniﬁcant in all groups. The model performed better in
absolute risk prediction in Denmark and the United Kingdom than in
The Netherlands. Conclusions: The UKPDS outcomes model has
moderate discriminatory ability in the ADDITION-Europe trial cohort
but overestimated absolute risk. The model may need updating for
cardiovascular disease risk prediction in contemporary diabetes
populations where patients may be diagnosed earlier in the disease
trajectory and in whom cardiovascular risk is therefore lower.
Keywords: ADDITION-Europe, diabetes, UKPDS outcomes model,
validation.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Background
Type 2 diabetes (T2D) is a chronic condition associated with
signiﬁcant disease burden and treatment costs, particularly for
cardiovascular disease (CVD). Accurate prediction of CVD risk
among people with T2D is important for targeting therapy to
those at highest risk and for providing prognostic information. It
is also a key component of economic evaluations of interventions
aimed at improving the quality and length of life and reducing
the disease burden of people with T2D.
The UK Prospective Diabetes Study (UKPDS) outcomes model
(UKPDS-OM) is a cost-effectiveness analysis tool that was
derived from the UKPDS, a multicenter randomized trial in
5102 newly diagnosed patients with T2D, recruited from 23 UK
centers [1]. The UKPDS-OM has been validated both internally
and externally among people with clinically diagnosed diabetes
for prediction of CVD and other complications. In internalvalidation analysis, the observed and modeled cumulative inci-
dence of CVD complications and all-cause mortality from diag-
nosis of diabetes to 12 years of follow-up was well matched [2].
In external validation studies, results varied from poor to
moderate in terms of absolute risk, discrimination, and calibra-
tion [3–7]. In general, the UKPDS-OM tends to overestimate the
risk of CVD [3,6,7].
The UKPDS-OM was developed by using data from patients
who were recruited between 1977 and 1997. Since that time, the
treatment of T2D and related conditions, as well as the cost of
treatment, has changed. The variables assessed by the UKPDS-
OM, including baseline characteristics, patient history, and clin-
ical efﬁcacy, are also likely to vary between countries. In addition,
many health systems have introduced screening programs to
detect diabetes earlier in the course of the disease. Consequently,
there is a need to evaluate the performance of the UKPDS-OM in
contemporary cohorts in different countries.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
gy Unit, Institute of Metabolic Science, Box 285, Addenbrooke’s
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People with Screen Detected Diabetes in Primary Care (ADDI-
TION-Europe) is a primary care–based study of screening for T2D
followed by a pragmatic open-label cluster randomized con-
trolled trial comparing intensive multifactorial treatment (IT)
with routine care (RC). The study was conducted over 5 years in
three European countries: Denmark, the United Kingdom, and
The Netherlands [8,9]. We aimed to assess the performance of the
UKPDS-OM in predicting CVD risk in the ADDITION-Europe pop-
ulation, and thus to investigate its suitability in modeling longer
term outcomes and costs for the ADDITION-Europe cohort.Methods
Detailed information about the ADDITION-Europe study design
and the main ﬁndings have been reported elsewhere [8,9]. In
brief, 343 general practices were cluster randomized to screening
plus RC of diabetes (176 general practitioners with 1379 partic-
ipants) or screening followed by IT (167 general practitioners with
1678 participants). Allocation was concealed from patients
throughout the trial. Following population-based stepwise
screening programs among people aged 40 to 69 years (50–69
years in The Netherlands), 3057 of 3233 (95%) eligible participants
with screen-detected diabetes agreed to take part (Denmark:
1533, United Kingdom: 1026, and The Netherlands: 498). Two
participants withdrew during the trial period. The study was
approved by local ethics committees in each center. All partic-
ipants provided informed consent. The clinical trial registration
number is NCT00237549.
In the IT group, the intensiﬁcation of diabetes management
was achieved through the addition of a number of features to
existing diabetes care alongside lifestyle advice concerning diet,
physical activity, and tobacco consumption and a stepwise
target-led drug treatment regime to reduce hyperglycemia, blood
pressure, hyperlipidemia, and microalbuminuria. RC practices
followed national guidelines for diabetes management.
Measurement and Outcomes
Health assessments, at baseline and after 5 years, included
biochemical and anthropometric measures, and were undertaken
by centrally trained staff, who were blind to the study group
allocation, following standard operating procedures. Standar-
dized self-report questionnaires were used to collect information
on sociodemographic characteristics (age, gender, and ethnicity),
lifestyle habits (smoking status), and history of cardiovascular
disease. Participants were followed for a median of 5.9 years. The
primary outcome was time to cardiovascular event, including
cardiovascular mortality, cardiovascular morbidity (nonfatal MI
and nonfatal stroke), revascularization, and nontraumatic ampu-
tation. Participants’ medical records and national registries were
searched for potential end points by staff blind to group alloca-
tion. All events were independently adjudicated by two members
of the local end point steering committee who were also blind to
the group allocation according to an agreed protocol by using
standardized case report forms. Because revascularization is not
a component of the UKPDS-OM and only a single case of
amputation was reported during follow-up, only MI and stroke
events were examined in this analysis.
The 5-year accumulated absolute risks of MI and stroke were
estimated for each participant in ADDITION-Europe by using the
UKPDS-OM (version 1.3) [10]. This is a T2D-speciﬁc risk assessment
tool that can be used to predict the annual risk of CVD events
including MI and stroke. The model includes information on age at
diagnosis, gender, ethnicity, duration of diabetes, weight, height,
smoking status, presence or absence of atrial ﬁbrillation (AF) andperipheral vascular disease (PVD), systolic blood pressure (SBP),
glycosylated hemoglobin A1c (HbA1c), total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), and years since preexist-
ing CVD events. Values of smoking status, SBP, HbA1c, TC, and
HDL-C were included at both baseline and 5-year follow-up.
Because information on AF and PVD was not collected at
baseline in the ADDITION-Europe study, and given that all patients
had newly diagnosed diabetes, these variables were set to 0.
Number of years since preexisting ischemic heart disease, con-
gestive heart failure, amputation, blindness, and renal failure
were also set to 0 because this information was also not collected
at baseline. Data on the number of years since any previous MI or
stroke were collected in the ADDITION-Europe study and entered
as appropriate into the model.
Statistical Analysis
We summarized baseline characteristics separately by center,
and calculated actual 5-year rates of MI and stroke and compared
them with the estimated risks over 5 years by using the UKPDS-
OM. The baseline characteristics of UKPDS cohort were also
included for comparison [11]. We used multiple imputation to
deal with missing data [12,13] by using the Markov chain Monte
Carlo method and assuming an arbitrary missing pattern. A
multivariate normal distribution was used to impute missing
values of age, gender, weight, height, smoking status, TC, HDL-C,
SBP, and HbA1c. It has been demonstrated in a previous study [14]
that multivariate normal imputation is less biased than
complete-case analysis, and produced similar results to other
approaches despite the presence of binary and ordinal variables
that did not follow a normal distribution. If the imputed HDL-C
value was greater than the TC value, we assumed that HDL-C
(mmol/l) ¼ TC – 0.1 (ﬁve cases at baseline; one case at ﬁnal follow-
up). For each patient with missing data, we undertook ﬁve
imputations and computed the average of the ﬁve risk estimates
[15].
In UKPDS-OM, the values of ethnicity were White-Caucasian,
Afro-Caribbean, and Asian-Indian. In the ADDITION-Europe cohort,
there were some unknown or unclassiﬁable values, for example,
mixed white þ African, mixed white þ Asian, or others. These
cases were unavoidably excluded from the analysis because
ethnicity is unsuitable for multiple imputation (156 cases).
The ratio of mean predicted versus actual CVD rate was
calculated and compared between intervention groups and
countries. A t test was performed to compare the absolute
difference between actual and mean predicted rates. We reported
the predicted risks of MI and stroke for patients who did or did
not experience the event in the trial. We examined the discrim-
ination of the UKPDS-OM by computing the area under the
receiver operating characteristic curve (aROC) and assessed good-
ness of ﬁt by using the Hosmer and Lemeshow chi-square test.
The same methods have been used in previous studies for the
validation of the UKPDS and Framingham risk engines [4,6,16].
In UKPDS-OM, both MI and stroke are assigned a particular
Weibull regression equation with age, gender, HbA1c, and other
variables as covariates [2]. To examine which distribution was the
best ﬁt for baseline risk of MI and stroke, we performed a number
of survival regression analyses including exponential, log-nor-
mal, log-logistic, Weibull, and generalized gamma. We computed
minimal Bayesian information criterion and Akaike’s information
criterion values to assess global model ﬁt [17]. We then analyzed
the covariates with the best ﬁt distribution to determine whether
they were signiﬁcantly associated with MI and stroke. A P value
of less than 0.10 was deﬁned as statistically signiﬁcant [18].
Because risk factor values were not available for every year of
follow-up in the ADDITION-Europe trial cohort, the average of
baseline and ﬁnal follow-up values was used.
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examine whether results were replicated, after excluding
patients for whom there was missing data (n ¼ 781/2899; 26.9%).
Statistical analyses were performed with the Statistics Anal-
ysis System (SAS, version 9.3).Results
From the 3055 ADDITION-Europe participants, 156 patients were
excluded because of unclassiﬁable or unknown ethnicity. There-
fore, data on 2899 patients were used in this analysis. Age, gender,
treatment group, and baseline HbA1c values were not signiﬁcantly
different between the included and excluded patients.
The mean age of participants was 60.3  6.9 years; 42.0% were
female, and 96.3% were Caucasian (Table 1). The mean HbA1c value
at baseline was 7.0%  1.6%. Baseline characteristics were not
signiﬁcantly different between the three countries for age. There
were larger numbers of women and individuals with Caucasian
ethnicity in The Netherlands and Denmark than in the United
Kingdom. Smoking rates were highest in Denmark and lowest in
the United Kingdom. Conversely, the mean body mass index (BMI)
was highest in the United Kingdom and lowest in Denmark. There
was no clear trend for biochemical values across the centers, but
systolic blood pressure was signiﬁcantly higher in The Netherlands
(165 mm Hg) than in the United Kingdom (149 mm Hg) and
Denmark (143 mm Hg). Compared with the ADDITION-Europe
cohort, the UKPDS cohort was younger, had slightly more men,
had larger numbers of nonwhite participants, and lower levels of
BMI, HDL-C cholesterol, and systolic blood pressure at baseline.
HbA1c levels were similar between the two cohorts (Table 1).Actual and Predicted Event Rates
The MI rate in ADDITION-Europe was 0.0228. The overall predicted
rate was 0.0681  0.0486, and 0.0941  0.0545 and 0.0658  0.0474
for patients who did or did not experience an MI, respectively. For
stroke, the actual rate was 0.0152 and the predicted rate was
0.0232  0.0206 for patients who did experience stroke, and the
actual rate was 0.0340  0.0270 and the predicted rate was 0.0223
 0.0197 for patients who did not experience stroke.Table 1 – Baseline characteristics of the UKPDS and ADD
Characteristic UKPDS A
All centers Denma
N 3642 2899 1452
Mean age  SD (y) 53  8.0 60.3  6.9 60.0  6
Female sex (%) 40 42.0 42.9
Caucasian ethnicity (%) 82 96.3 98.6
Current smoker (%) – 27.0 33.9
Mean BMI  SD (kg/m2) 27.7  5.3 31.6  5.6 30.8  5
Mean total cholesterol  SD
(mmol/L)
– 5.6  1.2 5.7  1
Mean HDL-C  SD (mmol/L) 1.1  0.24 1.3  0.4 1.4  0
Mean systolic blood pressure
 SD (mm Hg)
135.0  19 149.1  21.8 148.8  2
Mean HbA1c  SD (%) 7.1  1.8 7.0  1.6 6.8  1
ADDITION, Anglo-Danish-Dutch study of Intensive Treatment In PeOple
variance; BMI, body mass index; HbA1c, hemoglobin A1c; HDL-C, high-de
 P value from ANOVA or chi-square tests for the comparison of ADDITIEvent rates predicted with the UKPDS-OM were higher than
those observed in ADDITION-Europe. The ratio of predicted to
actual 5-year accumulated risk was 2.31 in the RC group and 3.97
in the IT group for MI, and 1.59 and 1.48 for stroke, respectively.
Because of the skewed distribution of predicted rates, the median
was smaller than the mean; nevertheless, the UKPDS model also
overestimated CVD event rates when the median was used.
When data were disaggregated by country, the overestimation
was higher in The Netherlands than in Denmark and the United
Kingdom for both MI and stroke (Table 2).
Examination of the absolute event rates between intervention
groups represents the impact of IT compared with RC. For MI, the
difference between intervention groups was higher than that
predicted by the UKPDS-OM: the actual difference was 0.0127 (RC
− IT ¼ 0.0297 − 0.0170), and the predicted difference was only
0.0009 (RC − IT ¼ 0.0686 − 0.0677), which means that the UKPDS-
OM underestimated the effect of intensive treatment. For stroke,
the difference was much smaller: −0.0013 (RC − IT ¼ 0.0145 −
0.0158) from the observed data and −0.0004 (RC − IT ¼ 0.0230 −
0.0234) from the predicted data, indicating slight overestimation.
Discrimination Analysis
The aROC was 0.72 (95% conﬁdence interval 0.66–0.79) for MI and
0.70 (95% conﬁdence interval 0.64–0.77) for stroke, indicating that the
UKPDS-OM had moderate discriminatory ability for MI and stroke
(Table 3). The Netherlands had the lowest aROC for MI (0.69) and the
highest for stroke (0.79). Results from the Hosmer-Lemeshow test
were nonsigniﬁcant both in the overall trial population and in each
country, suggesting that goodness of ﬁt was acceptable.
Survival Regression Analysis
Survival analysis showed that for both MI and stroke, an expo-
nential distribution provided the best ﬁt for baseline risk based on
Bayesian information criterion values. In addition, for Akaike’s
information criterion values, log-normal and exponential distri-
butions provided the best ﬁt for MI and stroke, respectively
(Table 4). On this basis, the exponential distribution was used in
survival regression analysis with a selection of covariates: age,
gender, treatment group, smoking status, BMI, HbA1c, SBP, and Ln
(TC/HDL-C) for MI or TC/HDL-C for stroke. Results showed that age,ITION-Europe trial cohorts.
DDITION P values (ANOVA or
chi-square test)*
rk The
Netherlands
United
Kingdom
448 999
.9 60.6  5.3 60.6  7.4 0.05
46.0 38.7 0.02
99.6 91.5 o0.001
25.0 18.0 0.01
.5 31.0  5.3 33.0  5.8 o0.001
.1 5.6  1.1 5.4  1.2 o0.001
.4 1.1  0.4 1.2  0.3 o0.001
0.2 164.7  23.3 142.7  19.8 o0.001
.5 7.3  1.4 7.3  1.7 o0.001
with screeN detected diabetes in primary care; ANOVA, analysis of
nsity lipoprotein cholesterol; UKPDS, UK Prospective Diabetes Study.
ON-Europe centers.
Table 2 – Actual and predicted MI and stroke event rates, by country and intervention group.
Event Center Intervention N Actual rate Predicted rate, mean  SD P/A* P†
MI All centers RC 1314 0.0297 0.0686  0.0477 2.31 o0.001
IT 1585 0.0170 0.0677  0.0494 3.97 o0.001
Denmark RC 601 0.0416 0.0646  0.0443 1.55 o0.001
IT 851 0.0165 0.0616  0.0418 3.74 o0.001
The Netherlands RC 212 0.0094 0.0845  0.0526 8.96 o0.001
IT 236 0.0085 0.0874  0.0626 10.32 o0.001
United Kingdom RC 501 0.0240 0.0667  0.0481 2.79 o0.001
IT 498 0.0221 0.0687  0.0516 3.11 o0.001
Stroke All centers RC 1314 0.0145 0.0230  0.0190 1.59 o0.001
IT 1585 0.0158 0.0234  0.0218 1.48 o0.001
Denmark RC 601 0.0133 0.0224  0.0180 1.69 o0.001
IT 851 0.0141 0.0205  0.0178 1.46 o0.001
The Netherlands RC 212 0.0094 0.0300  0.0224 3.18 o0.001
IT 236 0.0085 0.0363  0.0319 4.29 o0.001
United Kingdom RC 501 0.0180 0.0208  0.0180 1.16 o0.001
IT 498 0.0221 0.0221  0.0198 1.00 0.490
IT, intensive multifactorial treatment group; MI, myocardial infarction; RC, routine care group.
 P/A, mean predicted rate/actual rate.
† From t tests comparing mean predicted and actual rates.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 7 4 – 1 0 8 0 1077gender, and HbA1c were signiﬁcantly associated with MI, whereas
only age and gender were signiﬁcantly associated with stroke.
Complete Case Analysis
There were 2118 (from 2899) patients included in the complete case
analysis. Compared with excluded patients because of missing
data, the complete set had a lower mean age (60.1/60.8), a higher
proportion of men (59.0%/55.3%), and a higher mean HbA1c value
(7.06/6.96). The difference in mean age was statistically signiﬁcant.
In general, results were similar compared with the main imputed
analysis in terms of predicted/actual ratios and best ﬁt distribution.
The only exception was in survival analysis, where gender no
longer remained signiﬁcantly associated with stroke and HbA1c
became signiﬁcant.Discussion
The UKPDS-OM had moderate discriminatory ability among high-
risk individuals in the ADDITION-Europe trial cohort. The model,Table 3 – Discrimination and calibration analysis results
Europe trial cohort data.
Event Center aROC (95% CI)
MI All centers 0.72 (0.66–0.79)
Denmark 0.76 (0.66–0.85)
The Netherlands 0.69 (0.45–0.94)
United Kingdom 0.70 (0.59–0.81)
Stroke All centers 0.70 (0.64–0.77)
Denmark 0.76 (0.68–0.84)
The Netherlands 0.79 (0.55–1.00)
United Kingdom 0.65 (0.54–0.76)
ADDITION, Anglo-Danish-Dutch study of Intensive Treatment In PeOple
receiver operating characteristic curve; CI, conﬁdence interval; MI, myochowever, tended to overestimate the absolute risk of both MI and
stroke. Our results suggest that the model might need updating
for predicting CVD risk in contemporary diabetes populations
where patients may be diagnosed earlier in the disease trajectory
and in whom cardiovascular risk is therefore lower.
The UKPDS-OM (version 1.3) overestimated 5-year absolute
risk of MI and stroke in the ADDITION-Europe cohort, although
the accuracy varied between countries, with particularly poor
performance for The Netherlands compared with Denmark and
the United Kingdom. One reason for the relatively poor prediction
could be differences in baseline characteristics between the
ADDITION and UKPDS cohorts. The UKPDS population had some
baseline characteristics associated with a lower risk of CVD
including lower mean age, mean BMI, and mean SBP, although
some characteristics would lead to higher risk (more male
participants, lower mean HDL-C, and slightly higher mean
HbA1c). The impact of baseline characteristics was therefore
likely to be mixed. For The Netherlands, mean SBP was higher
than in the UKPDS cohort (165 mm Hg vs. 135 mm Hg).
The purpose of the UKPDS model, however, is to supply the
coefﬁcients for the inputted risk factors. Therefore, the accuracyfor the UKPDS outcomes model using ADDITION-
Chi-squared value from
Hosmer-Lemeshow test
P value from Hosmer-
Lemeshow test
9.79 0.28
7.61 0.47
7.11 0.53
8.01 0.43
9.10 0.33
7.59 0.47
7.17 0.52
6.07 0.64
with screeN detected diabetes in primary care; aROC, area under the
ardial infarction; UKPDS, UK Prospective Diabetes Study.
Table 4 – Goodness of ﬁt of baseline risk and covariates of survival regression analysis using ADDITION-
Europe data.
Event Distribution BIC AIC Signiﬁcant covariates (P 4 0.10, from the exponential distribution)
MI Gamma 656.12 585.50
Age, gender, HbA1c
Exponential 641.45* 583.43
Log-logistic 648.95 585.13
Log-normal 646.98 583.16*
Weibull 649.24 585.43
Stroke Gamma 434.02 364.41
Age, gender
Exponential 418.54* 360.50*
Log-logistic 426.21 362.39
Log-normal 426.27 362.45
Weibull 426.21 362.40
ADDITION, Anglo-Danish-Dutch study of Intensive Treatment In PeOple with screeN detected diabetes in primary care; AIC, Akaike’s
information criterion; BIC, Bayesian information criterion; HbA1c, hemoglobin A1c; MI, myocardial infarction.
 The exponential distribution provided the overall best ﬁt model.
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line characteristics: it would be reasonable to reject a model on
the basis of baseline characteristics only if the two populations
were very different (e.g., predicting the risk of heart disease on
the basis of a cohort of 80-year-olds and applying it to a cohort of
20-year-olds). The most likely explanation for the overestimation
of events is due to improvements in treatment and care between the
time the UKPDS data were collected (enrolment period 1977–1997)
and the ADDITION-Europe data collection (2002–2006). Further-
more, the ADDITION-Europe intervention comprised a much more
comprehensive set of preventative therapies administered from
an earlier stage in the disease than would be routinely offered.
Finally, our ﬁndings are consistent with other studies exploring
the applicability of the UKPDS and Framingham models in popu-
lations with low disease rates [6,7].
When inputting data into the UKPDS risk engine, we set AF
and PVD to 0 because these data were not collected at baseline in
the ADDITION-Europe trial. PVD was a risk factor only for ampu-
tation (odds ratio ¼ 11.4) in the UKPDS-OM. Because we focus on
MI and stroke in our analysis, the omission of this data will not
affect our results. AF is a risk factor for stroke (odds ratio ¼ 4.2) in
the UKPDS-OM [2], suggesting that missing data for this variable
would likely underestimate the risk of stroke. Previous studies,
however, show that the prevalence of AF ranges from 1.2% to
2.8% in people aged 60 years [19,20], and so missing data for this
variable are unlikely to have a large impact on our ﬁndings.
Although this analysis showed that the UKPDS-OM tended to
overestimate the risk of MI and stroke in each arm of the
ADDITION-Europe study, its performance varied in predicting the
difference between intervention groups. The assessment of the
cost-effectiveness of health care interventions requires knowledge
of the increment between the comparators, rather than the
absolute levels of each. In our study, the UKPDS-OM underesti-
mated the incremental incidence in MI between arms (RC-IT) and
slightly overestimated the difference for stroke. Whether these
differences could be sufﬁcient to render the UKPDS unsuitable to
extrapolate the ADDITION data remains ultimately a subjective
decision. The insight that this analysis provides is that if the
UKPDS-OM is unadjusted, it will underestimate any reductions in
MI attributable to intensive treatment, therefore potentially under-
estimating the cost-effectiveness of the intensive intervention. The
small disparity in the predicted rate versus the actual rate of stroke
may be of limited consequence due to the effects of discounting.
The UKPDS-OM had moderate discriminatory ability for predict-
ing MI and stroke. The aROC ranged from 0.65 to 0.79 [21]. None of
the Hosmer-Lemeshow tests was statistically signiﬁcant, showingthat the goodness of ﬁt was not unacceptable. We found a discrep-
ancy between absolute risk prediction andmodel predicted risk. One
possible explanation for this discrepancy is the insensitivity of the
aROC and Hosmer-Lemeshow tests; previous studies have shown
that different pairs of predicted and actual risk can have the same
contribution to the aROC [22,23]. Despite their shortcomings, these
tests are routinely adopted in analyses of this sort. We therefore
present the results but caution against overinterpretation.
The UKPDS-OM was based on a set of survival regression
equations. It is essential to choose a suitable baseline distribution
and covariates for the model to perform successfully. In the UKPDS-
OM, the Weibull distribution was applied for all CVD events [2]. The
best-ﬁt model for the ADDITION-Europe data, however, was an
exponential distribution. This showed that age, gender, and HbA1c
were signiﬁcant predictors of MI, while age and gender were
signiﬁcant for stroke. In previous studies, many risk factors such
as age, gender, blood pressure, AF, renal failure, dyslipidemia, and
heart failure have been linked to CVD risk [24,25]. Our analyses
indicated that age, gender, and HbA1c were important covariates and
should be included in the UKPDS-OM. In the UKPDS cohort, the
researchers collected biochemistry data every year and applied the
values taken at the year of the event in their regression analysis [2].
Because we did not collect data annually in ADDITION-Europe, we
averaged baseline and follow-up values of SBP, HDL-C, TC, and
HbA1c and applied these values at the year of the event in the
regression analysis. This pragmatic decision may have contributed
to the observed differences between the UKPDS-OM and our results.Strengths, Limitations, and Further Study
In this study, we examined the performance of the UKPDS-OM for
both MI and stroke in different countries and between intervention
groups. The strengths of the ADDITION-Europe trial cohort include
the large sample size with participants from three European coun-
tries and robust CVD end point ascertainment. We used multiple
imputations to handle missing data, which allowed the best use of
the available data while taking into account the uncertainty in
missing values. Alternatively, the exclusion of incomplete observa-
tions would lead to considerable loss of data. Previous research has
suggested that for this reason multiple imputation is the preferable
method for handling missing data. It is, however, at the expense of a
greater number of assumptions, which might inﬂuence the analysis
[26,27]. In our study, both the imputed data set and the complete
case data set produced similar results, which conﬁrmed that our
analysis was robust. Limitations include the lack of detailed annual
risk factor measurement and the lack of information on AF, PVD,
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 7 4 – 1 0 8 0 1079and years since preexisting CVD conditions, blindness, and renal
failure at baseline. This might have impacted the efﬁciency of the
model and introduced some bias in the model prediction, mostly
likely contributing to an underestimation of CVD risk.
Furthermore, the follow-up time was 5 years in the ADDITION-
Europe trial cohort. We validated the UKPDS-OM by using short-
term data with a view of extrapolating our data to a longer time
horizon to estimate the lifetime incremental cost-effectiveness of
intensive multifactorial therapy. As follow-up continues, more
events will occur. Once longer term data are available, we will be
able to revise our estimate of the longer term cost-effectiveness
of the intervention.Conclusions
The UKPDS-OM overestimated the 5-year cumulative absolute
risk of MI and stroke in the ADDITION-Europe cohort but had
moderate discriminatory ability for predicting MI and stroke.
The difference in absolute risk between the intervention groups
was underestimated for MI and slightly overestimated for
stroke. Use of the model to extrapolate ADDITION-Europe data
may be possible, but any reductions in MI may be underesti-
mated. Interpretation of the results of any cost-effectiveness
analysis should take account of this caveat, and appropriate
sensitivity analyses should be conducted adjusting for the
difference in risk.Acknowledgments
We gratefully acknowledge the contribution of all participants,
practice nurses, and general practitioners in the ADDITION-Europe
study. We are grateful to the independent end point committee in
Denmark (Professors Kristian Thygesen, Hans Ibsen, Ole Færge-
man, and Birger Thorsteinsson), the United Kingdom (Professor
Jane Armitage and Dr. Louise Bowman), and The Netherlands
(Professors Cees Tack and Jaap Kappelle). We thank Dr. Clare
Boothby (MRC Epidemiology Unit, UK) for her assistance with
data cleaning, the Diabetes Trials Unit at Oxford University for
the UKPDS-OM license, and the Health Economics Group at the
University of East Anglia for methodological advice.
Source of ﬁnancial support: ADDITION-Cambridge was sup-
ported by the Wellcome Trust (grant reference no. G061895); the
Medical Research Council (grant reference no. G0001164); the
National Institute for Health Research (NIHR) Health Technology
Assessment Program (grant reference no. 08 ⁄ 116 ⁄ 300); National
Health Service R&D support funding (including the Primary Care
Research and Diabetes Research Networks); and the National
Institute for Health Research. S.J.G. receives support from the
Department of Health NIHR Program Grant funding scheme (RP-
PG-0606-1259). The views expressed in this publication are those of
the authors and not necessarily those of the UK Department of
Health. Bio-Rad provided equipment for HbA1c testing during the
screening phase. ADDITION-Denmark was supported by the
National Health Services in the counties of Copenhagen, Aarhus,
Ringkøbing, Ribe, and South Jutland in Denmark; the Danish
Council for Strategic Research; the Danish Research Foundation
for General Practice; Novo Nordisk Foundation; the Danish Centre
for Evaluation and Health Technology Assessment; the diabetes
fund of the National Board of Health; the Danish Medical Research
Council; and the Aarhus University Research Foundation. The trial
has been given unrestricted grants from Novo Nordisk AS, Novo
Nordisk Scandinavia AB, Novo Nordisk UK, ASTRA Denmark, Pﬁzer
Denmark, GlaxoSmithKline Pharma Denmark, Servier Denmark
A⁄ S, and HemoCue Denmark A⁄ S. Parts of the grants from the
Novo Nordisk Foundation, the Danish Council for StrategicResearch, and Novo Nordisk were transferred to the other centers.
ADDITION-Leicester was supported by the Department of Health
and ad hoc Support Sciences; the NIHR Health Technology Assess-
ment Program (grant reference no. 08 ⁄ 116 ⁄ 300); National Health
Service R&D support funding (including the Primary Care Research
and Diabetes Research Network, and LNR CLAHRC); and the
National Institute for Health Research. M.J.D. and K.K. receive
support from the Department of Health NIHR Program Grant
funding scheme (RP-PG-0606- 1272). ADDITION-Netherlands was
supported by unrestricted grants from Novo Nordisk, Glaxo Smith
Kline, and Merck and by the Julius Center for Health Sciences and
Primary Care, University Medical Center, Utrecht.
R E F E R E N C E S[1] UK Prospective Diabetes Study (UKPDS). Study design, progress and
performance. Diabetologia 1991;34:877–90.
[2] Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime
health outcomes of patients with type 2 diabetes: The United Kingdom
Prospective Diabetes Study (UKPDS) outcomes model. Diabetologia
2004;47:1747–59.
[3] McEwan P, Bergenheim K, Currie C. External validation of the UKPDS
outcomes model equations and the UKPDS risk engine equations in
forecasting cardiovascular outcomes in people with type 2 diabetes.
Value Health 2006;9:2.
[4] Simmons RK, Coleman RL, Price HC, et al. Performance of the UK
Prospective Diabetes Study risk engine and the Framingham risk
equations in estimating cardiovascular disease in the EPIC-Norfolk
cohort. Diabetes Care 2009;32:708–13.
[5] Guzder RN, Gatling W, Mullee MA, et al. Prognostic value of the
Framingham cardiovascular risk equation and the UKPDS risk engine
for coronary heart disease in newly diagnosed type 2 diabetes: results
from a United Kingdom study. Diabet Med 2005;22:554–62.
[6] Coleman RL, Stevens RJ, Retnakaran R, et al. Framingham score and
DECODE risk equations do not provide reliable cardiovascular risk
estimates in type 2 diabetes. Diabetes Care 2007;30:1292–3.
[7] Kengne AP, Patel A, Colagiuri S, et al. The Framingham and UK
Prospective Diabetes Study (UKPDS) risk equations do not reliably
estimate the probability of cardiovascular events in a large ethnically
diverse sample of patients with diabetes. Diabetologia
2010;53:821–31.
[8] Grifﬁn SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive
multifactorial therapy on 5-year cardiovascular outcomes in
individuals with type 2 diabetes detected by screening (ADDITION-
Europe): a cluster-randomised trial. Lancet 2011;11:156–67.
[9] Lauritzen T, Grifﬁn S, Borch-Johnsen K, et al. The ADDITION study:
proposed trial of the cost-effectiveness of an intensive multifactorial
intervention on morbidity and mortality among people with type 2
diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24
(Suppl. 3):S6–11.
[10] UKPDS outcomemodel. Version 1.3 © Isis innovation ltd 2010. Available
from: http://www.dtu.ox.ac.uk/outcomesmodel. [Accessed December 7,
2011].
[11] Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia
with macrovascular and microvascular complications of type 2
diabetes (UKPDS 35): prospective observational study. BMJ
2000;321:405–12.
[12] Rubin DB, Schenker N. Multiple imputation in health-care databases:
an overview and some applications. Stat Med 1991;10:585–98.
[13] Yuan Y. Multiple imputation using SAS software. J Stat Softw
2011;45:1–25.
[14] Lee KJ, Carlin JB. Multiple imputation for missing data: fully conditional
speciﬁcation versus multivariate normal imputation. Am J Epidemiol
2010;171:624–32.
[15] Rubin DB. Mutliple Imputation for Nonresponse in Surveys. Hoboken,
NJ: Wiley, 2004.
[16] Van Dieren S, Peelen LM, Nothlings U, et al. External validation of the
UK Prospective Diabetes Study (UKPDS) risk engine in patients with
type 2 diabetes. Diabetologia 2011;54:264–70.
[17] Jones RH. Bayesian information criterion for longitudinal and clustered
data. Stat Med 2011;30:3050–6.
[18] Velentgas P, Dreyer NA, Nourjah P, et al., eds. Developing a Protocol for
Observational Comparative Effectiveness Research: A User’s Guide.
Rockville, MD: Agency for Healthcare Research and Quality (AHRQ),
2013. http://effectivehealthcare.ahrq.gov/ehc/products/440/1166/
User-Guide-Observational-CER-130113.pdf. [Accessed July 10, 2013].
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 0 7 4 – 1 0 8 01080[19] Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed
atrial ﬁbrillation in adults: national implications for rhythm
management and stroke prevention: the AnTicoagulation and
Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA
2001;285:2370–5.
[20] Davis RC, Hobbs FD, Kenkre JE, et al. Prevalence of atrial ﬁbrillation in
the general population and in high-risk groups: the ECHOES study.
Europace 2012;14:1553–9.
[21] Swets JA. Measuring the accuracy of diagnostic systems. Science
1988;240:1285–93.
[22] Meistrell ML. Evaluation of neural network performance by receiver
operating characteristic (ROC) analysis: examples from the
biotechnology domain. Comput Methods Programs Biomed
1990;32:73–80.[23] Cook NR. Statistical evaluation of prognostic versus diagnostic models:
beyond the ROC curve. Clin Chem 2008;54:17–23.
[24] Merida-Rodrigo L, Poveda-Gomez F, Camafort-Babkowski M, et al. Long-
term survival of ischemic stroke. Rev Clin Esp 2012;212:223–8.
[25] Ukena C, Dobre D, Mahfoud F, et al. Hypo- and hyperglycemia predict
outcome in patients with left ventricular dysfunction after acute
myocardial infarction: data from ephesus. J Card Fail 2012;18:439–45.
[26] Sinharay S, Stern HS, Russell D. The use of multiple imputation for the
analysis of missing data. Psychol Methods 2001;6:317–29.
[27] Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing
data in epidemiological and clinical research: potential and pitfalls. BMJ
2009;339:b2398.
